167 related articles for article (PubMed ID: 34753870)
41. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
[TBL] [Abstract][Full Text] [Related]
42. Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.
Bull ME; McKernan JL; Styrchak S; Kraft K; Hitti J; Cohn SE; Tapia K; Deng W; Holte S; Mullins JI; Coombs RW; Frenkel LM
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):557-566. PubMed ID: 30892052
[TBL] [Abstract][Full Text] [Related]
43. Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution.
Kauffman RC; Villalobos A; Bowen JH; Adamson L; Schinazi RF
PLoS One; 2014; 9(2):e88258. PubMed ID: 24505452
[TBL] [Abstract][Full Text] [Related]
44. Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth.
Brumme ZL; Sudderuddin H; Ziemniak C; Luzuriaga K; Jones BR; Joy JB; Cunningham CK; Greenough T; Persaud D
AIDS; 2019 Feb; 33(2):211-218. PubMed ID: 30325763
[TBL] [Abstract][Full Text] [Related]
45. Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites.
Lee E; von Stockenstrom S; Morcilla V; Odevall L; Hiener B; Shao W; Hartogensis W; Bacchetti P; Milush J; Liegler T; Sinclair E; Hatano H; Hoh R; Somsouk M; Hunt P; Boritz E; Douek D; Fromentin R; Chomont N; Deeks SG; Hecht FM; Palmer S
J Virol; 2020 Jan; 94(3):. PubMed ID: 31723024
[TBL] [Abstract][Full Text] [Related]
46. Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription.
Pannus P; Rutsaert S; De Wit S; Allard SD; Vanham G; Cole B; Nescoi C; Aerts J; De Spiegelaere W; Tsoumanis A; Couttenye MM; Herssens N; De Scheerder MA; Vandekerckhove L; Florence E
J Int AIDS Soc; 2020 Feb; 23(2):e25453. PubMed ID: 32107887
[TBL] [Abstract][Full Text] [Related]
47. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
Tebas P; Jadlowsky JK; Shaw PA; Tian L; Esparza E; Brennan AL; Kim S; Naing SY; Richardson MW; Vogel AN; Maldini CR; Kong H; Liu X; Lacey SF; Bauer AM; Mampe F; Richman LP; Lee G; Ando D; Levine BL; Porter DL; Zhao Y; Siegel DL; Bar KJ; June CH; Riley JL
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33571163
[TBL] [Abstract][Full Text] [Related]
48. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
[TBL] [Abstract][Full Text] [Related]
49. Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy.
Fennessey CM; Pinkevych M; Immonen TT; Reynaldi A; Venturi V; Nadella P; Reid C; Newman L; Lipkey L; Oswald K; Bosche WJ; Trivett MT; Ohlen C; Ott DE; Estes JD; Del Prete GQ; Lifson JD; Davenport MP; Keele BF
PLoS Pathog; 2017 May; 13(5):e1006359. PubMed ID: 28472156
[TBL] [Abstract][Full Text] [Related]
50. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.
Eriksson S; Graf EH; Dahl V; Strain MC; Yukl SA; Lysenko ES; Bosch RJ; Lai J; Chioma S; Emad F; Abdel-Mohsen M; Hoh R; Hecht F; Hunt P; Somsouk M; Wong J; Johnston R; Siliciano RF; Richman DD; O'Doherty U; Palmer S; Deeks SG; Siliciano JD
PLoS Pathog; 2013 Feb; 9(2):e1003174. PubMed ID: 23459007
[TBL] [Abstract][Full Text] [Related]
51. The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy.
McMyn NF; Varriale J; Fray EJ; Zitzmann C; MacLeod H; Lai J; Singhal A; Moskovljevic M; Garcia MA; Lopez BM; Hariharan V; Rhodehouse K; Lynn K; Tebas P; Mounzer K; Montaner LJ; Benko E; Kovacs C; Hoh R; Simonetti FR; Laird GM; Deeks SG; Ribeiro RM; Perelson AS; Siliciano RF; Siliciano JM
J Clin Invest; 2023 Sep; 133(17):. PubMed ID: 37463049
[TBL] [Abstract][Full Text] [Related]
52. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.
Bailey JR; Sedaghat AR; Kieffer T; Brennan T; Lee PK; Wind-Rotolo M; Haggerty CM; Kamireddi AR; Liu Y; Lee J; Persaud D; Gallant JE; Cofrancesco J; Quinn TC; Wilke CO; Ray SC; Siliciano JD; Nettles RE; Siliciano RF
J Virol; 2006 Jul; 80(13):6441-57. PubMed ID: 16775332
[TBL] [Abstract][Full Text] [Related]
53. Early antiretroviral therapy and its impact on natural killer cell dynamics in HIV-1 infected men who have sex with men: a cross-sectional pilot study evaluating the impact of early ART initiation on NK cell perturbation in HIV infection.
Akiso M; Muema D; Langat R; Naidoo KK; Oino G; Mutua G; Thobakgale C; Ochiel D; Chinyenze K; Anzala O; Mureithi MW
Microbiol Spectr; 2024 Apr; 12(4):e0357023. PubMed ID: 38364104
[TBL] [Abstract][Full Text] [Related]
54. Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report.
Gupta RK; Peppa D; Hill AL; Gálvez C; Salgado M; Pace M; McCoy LE; Griffith SA; Thornhill J; Alrubayyi A; Huyveneers LEP; Nastouli E; Grant P; Edwards SG; Innes AJ; Frater J; Nijhuis M; Wensing AMJ; Martinez-Picado J; Olavarria E
Lancet HIV; 2020 May; 7(5):e340-e347. PubMed ID: 32169158
[TBL] [Abstract][Full Text] [Related]
55. Harnessing CD8
Warren JA; Clutton G; Goonetilleke N
Front Immunol; 2019; 10():291. PubMed ID: 30863403
[TBL] [Abstract][Full Text] [Related]
56. Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy.
Gianella S; Kosakovsky Pond SL; Oliveira MF; Scheffler K; Strain MC; De la Torre A; Letendre S; Smith DM; Ellis RJ
Virus Evol; 2016 Jul; 2(2):vew020. PubMed ID: 27774305
[TBL] [Abstract][Full Text] [Related]
57. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.
Chun TW; Davey RT; Ostrowski M; Shawn Justement J; Engel D; Mullins JI; Fauci AS
Nat Med; 2000 Jul; 6(7):757-61. PubMed ID: 10888923
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of Heat Shock Protein 90 Prevents HIV Rebound.
Joshi P; Maidji E; Stoddart CA
J Biol Chem; 2016 May; 291(19):10332-46. PubMed ID: 26957545
[TBL] [Abstract][Full Text] [Related]
59. Brief Report: Toll-like Receptor 9-1635A/G Polymorphism Is Associated With HIV-1 Rebound After Four Weeks of Interruption of Antiretroviral Therapy.
Vallejo A; Molina-Pinelo S; de Felipe B; Abad-Fernández M; González-Escribano MF; Leal M; Soriano-Sarabia N
J Acquir Immune Defic Syndr; 2020 Oct; 85(2):252-256. PubMed ID: 32658127
[TBL] [Abstract][Full Text] [Related]
60. Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.
Sahu GK; Paar D; Frost SD; Smith MM; Weaver S; Cloyd MW
J Med Virol; 2009 Jan; 81(1):9-15. PubMed ID: 19031450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
